Kalmar Science Park - Lifesymb
| Reference number | |
| Coordinator | Kalmar Science Park AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | May 2016 - May 2017 |
| Status | Completed |
Important results from the project
The expected result of the project was the validation of the technology and the test of it against the current standard of measurement devices, the development of strategic partnerships, and the validation of the business model. The product launch was anticipated on 2017-02-01, but had to be postponed to 2017-10-01. The main reason was the difficulty to get in touch with decision-makers from the insurance world, which was finally achieved through a successful execution of the Startupbootcamp InsurTech Accelerator program in London.
Expected long term effects
LifeSymb succeed to validate its value proposition, business model and baseline technology together with decision makers from various major insurance companies, including Fidelidade (Portugal´s largest insurance company), AXA, HDI, Talanx and Zurich. The result is a contract with all those insurance companies. The purpose of the collaboration is to jointly launch the technology and to prove the reliability of the technology through a clinical study.
Approach and implementation
The existing prototype served as a baseline. Existing knowledge and new insights from the research study in Karlskrona was used to build a first commercial version of the technology. Together with Softwerk, Hotswap and the Linnaeus University we identified and developed all requirements to certify the technology AIMO as a medical device class 1, which is now ready for distribution.